Zinzino released its preliminary sales results for August 2026. Total group revenue grew 15% year-over-year to $28 million. Zinzino’s sales markets saw a 16% increase, reaching approximately $27.9 million, while Faun Pharma’s external sales fell from approximately $338,000 to approximately $130,000. In total, accumulated revenue for the first eight months of 2026 increased by 22%, totaling $245 million.
By market, South America (Peru, Colombia) saw the greatest year-over-year improvement, with 323% growth, followed by North America (59%), which includes Canada, the US and Mexico; Central Europe (32%), including Austria, Germany and Switzerland; and South Africa (18%).
Year-to-date, Central Europe brought in the highest revenue totals, with $73 million, followed by South and West Europe (Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Portugal, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey and Canary Islands) at $40 million.









